Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy

Wang,Daqing; Jiang,Wayne; Zhu,Fugang; Mao,Xianzhi; Agrawal,Sudhir

doi:10.3892/ijo.2018.4456

Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy

Authors:
- Daqing Wang
- Wayne Jiang
- Fugang Zhu
- Xianzhi Mao
- Sudhir Agrawal
View Affiliations

Affiliations: Idera Pharmaceuticals, Inc., Cambridge, MA 02139, USA
Published online on: June 27, 2018 https://doi.org/10.3892/ijo.2018.4456
Pages: 1193-1203

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The objective of cancer immunotherapy is to prime the host's immune system to recognize and attack malignant tumor cells. IMO‑2125, a Toll‑like receptor 9 (TLR9) agonist, exhibited potent antitumor effects in the murine syngeneic A20 lymphoma and the CT26 colon carcinoma models. IMO‑2125 exhibited superior A20 antitumor activity when injected intratumorally (i.t.) compared with equivalent subcutaneous doses. In mice bearing dual CT26 grafts, the i.t. injection of right flank tumors elicited infiltration of cluster of differentiation (CD)3+ T lymphocytes into tumors, resulting in the regression of injected and uninjected left flank tumors. Depletion of CD8+, but not CD4+, T‑cells abrogated the IMO‑2125‑mediated antitumor response, suggesting that CD8+ lymphocytes are required for the antitumor activity. In mice harboring right flank CT26 and left flank β‑galactosidase (β‑gal)‑expressing CT26.CL25 grafts, the i.t. administration of IMO‑2125 to the CT26 graft resulted in potent and dose‑dependent antitumor activity against the two grafts. Splenic T‑cells isolated from these mice responded to AH1 antigen (present in the two tumors) and β‑gal antigen (present only in CT26.CL25) in an interferon γ enzyme‑linked immunospot assay, suggesting the clonal expansion of T‑cells directed against antigens from the two tumors. Mice with ablated CT26 tumors by previous IMO‑2125 treatment rejected re‑implanted CT26 tumor cells, but not A20 tumor cells, demonstrating that the initial IMO‑2125 treatment created a long‑lived tumor‑specific immune memory of CT26 antigens. A quantitative increase in CD3+ T lymphocytes in injected A20 tumors and an upregulation of selected checkpoint genes, including indoleamine 2,3‑dioxygenase (IDO)‑1, IDO‑2, programmed cell death protein-1 (PD-1); programmed cell death protein ligand 1 (PD-L1), carcinoembryonic antigen‑related cell adhesion molecule 1, tumor necrosis factor receptor superfamily member 4 (OX40), OX40 ligand, T‑cell immunoglobulin and mucin‑domain‑containing 3 protein, lymphocyte‑activation gene 3, cytotoxic T‑lymphocyte‑associated protein 4, were observed following IMO‑2125 treatment. IMO‑2125 also increased immune checkpoint gene expression in injected and uninjected contralateral CT26 tumors, suggesting that the co‑administration of anti‑CTLA‑4, anti‑PD‑1 or anti‑PD‑L1 therapies with IMO‑2125 may provide additional therapeutic efficacy.

View Figures

View References

1	Alexander W: The Checkpoint Immunotherapy Revolution: What started as a trickle has become a flood, despite some daunting adverse effects; New drugs, indications, and combinations continue to emerge. PT. 41:185–191. 2016.
2	Fountzilas C, Patel S and Mahalingam D: Review: Oncolytic virotherapy, updates and future directions. Oncotarget. 8:102617–102639. 2017. View Article : Google Scholar : PubMed/NCBI
3	Yin J, Markert JM and Leavenworth JW: Modulation of the intratumoral immune landscape by oncolytic herpes simplex virus virotherapy. Front Oncol. 7:1362017. View Article : Google Scholar : PubMed/NCBI
4	Coley WB: The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases 1893 Clin Orthop Relat Res. 262:3–11. 1991.
5	Zbar B and Tanaka T: Immunotherapy of cancer: Regression of tumors after intralesional injection of living Mycobacterium bovis. Science. 172:271–273. 1971. View Article : Google Scholar : PubMed/NCBI
6	Cohen MH, Jessup JM, Felix EL, Weese JL and Herberman RB: Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: A randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochloro-benzene. Cancer. 41:2456–2463. 1978. View Article : Google Scholar : PubMed/NCBI
7	Morton DL, Eilber FR, Holmes EC, Hunt JS, Ketcham AS, Silverstein MJ and Sparks FC: BCG immunotherapy of malignant melanoma: Summary of a seven-year experience. Ann Surg. 180:635–643. 1974. View Article : Google Scholar : PubMed/NCBI
8	Silverstein MJ, DeKernion J and Morton DL: Malignant melanoma metastatic to the bladder. Regression following intratumor injection of BCG vaccine. JAMA. 229:6881974. View Article : Google Scholar : PubMed/NCBI
9	Krown SE, Hilal EY, Pinsky CM, Hirshaut Y, Wanebo HJ, Hansen JA, Huvos AG and Oettgen HF: Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma. Cancer. 42:2648–2660. 1978. View Article : Google Scholar : PubMed/NCBI
10	Bier J, Kleinschuster S, Bier H and Rapp H: Intratumor immunotherapy with BCG cell wall preparations: Development of a new therapy approach for head-neck tumors. Arch Otorhinolaryngol. 236:245–255. 1982.In German. View Article : Google Scholar
11	Bast RC Jr, Zbar B, Borsos T and Rapp HJ: BCG and cancer (first of two parts). N Engl J Med. 290:1413–1420. 1974. View Article : Google Scholar : PubMed/NCBI
12	Bast RC Jr, Zbar B, Borsos T and Rapp HJ: BCG and cancer. N Engl J Med. 290:1458–1469. 1974. View Article : Google Scholar : PubMed/NCBI
13	Shimada S, Yano O, Inoue H, Kuramoto E, Fukuda T, Yamamoto H, Kataoka T and Tokunaga T: Antitumor activity of the DNA fraction from Mycobacterium bovis BCG. II. Effects on various syngeneic mouse tumors. J Natl Cancer Inst. 74:681–688. 1985.PubMed/NCBI
14	Yamamoto S, Yamamoto T, Nojima Y, Umemori K, Phalen S, McMurray DN, Kuramoto E, Iho S, Takauji R, Sato Y, et al: Discovery of immunostimulatory CpG-DNA and its application to tuberculosis vaccine development. Jpn J Infect Dis. 55:37–44. 2002.PubMed/NCBI
15	Yu D, Kandimalla ER, Bhagat L, Tang JY, Cong Y, Tang J and Agrawal S: 'Immunomers' - novel 3′-3′-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res. 30:4460–4469. 2002. View Article : Google Scholar : PubMed/NCBI
16	Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, et al: A Toll-like receptor recognizes bacterial DNA. Nature. 408:740–745. 2000. View Article : Google Scholar : PubMed/NCBI
17	Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA and Klinman DM: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:546–549. 1995. View Article : Google Scholar : PubMed/NCBI
18	Mandl JN, Barry AP, Vanderford TH, Kozyr N, Chavan R, Klucking S, Barrat FJ, Coffman RL, Staprans SI and Feinberg MB: Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med. 14:1077–1087. 2008. View Article : Google Scholar : PubMed/NCBI
19	Zhao Q, Temsamani J, Iadarola PL, Jiang Z and Agrawal S: Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem Pharmacol. 51:173–182. 1996. View Article : Google Scholar : PubMed/NCBI
20	Kandimalla ER, Yu D, Zhao Q and Agrawal S: Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: Structure-immunostimulatory activity relationships. Bioorg Med Chem. 9:807–813. 2001. View Article : Google Scholar : PubMed/NCBI
21	Yu D, Zhao Q, Kandimalla ER and Agrawal S: Accessible 5′-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity. Bioorg Med Chem Lett. 10:2585–2588. 2000. View Article : Google Scholar : PubMed/NCBI
22	Kandimalla ER, Bhagat L, Yu D, Cong Y, Tang J and Agrawal S: Conjugation of ligands at the 5′-end of CpG DNA affects immunostimulatory activity. Bioconjug Chem. 13:966–974. 2002. View Article : Google Scholar : PubMed/NCBI
23	Kandimalla ER, Bhagat L, Wang D, Yu D, Zhu FG, Tang J, Wang H, Huang P, Zhang R and Agrawal S: Divergent synthetic nucleotide motif recognition pattern: Design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res. 31:2393–2400. 2003. View Article : Google Scholar : PubMed/NCBI
24	Yu D, Kandimalla ER, Zhao Q, Bhagat L, Cong Y and Agrawal S: Requirement of nucleobase proximal to CpG dinucleotide for immunostimulatory activity of synthetic CpG DNA. Bioorg Med Chem. 11:459–464. 2003. View Article : Google Scholar : PubMed/NCBI
25	Wang D, Li Y, Yu D, Song SS, Kandimalla ER and Agrawal S: Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs. Int J Oncol. 24:901–908. 2004.PubMed/NCBI
26	Damiano V, Caputo R, Bianco R, D'Armiento FP, Leonardi A, De Placido S, Bianco AR, Agrawal S, Ciardiello F and Tortora G: Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. Clin Cancer Res. 12:577–583. 2006. View Article : Google Scholar : PubMed/NCBI
27	Damiano V, Caputo R, Garofalo S, Bianco R, Rosa R, Merola G, Gelardi T, Racioppi L, Fontanini G, De Placido S, et al: TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proc Natl Acad Sci USA. 104:12468–12473. 2007. View Article : Google Scholar : PubMed/NCBI
28	Damiano V, Garofalo S, Rosa R, Bianco R, Caputo R, Gelardi T, Merola G, Racioppi L, Garbi C, Kandimalla ER, et al: A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action. Clin Cancer Res. 15:6921–6930. 2009. View Article : Google Scholar : PubMed/NCBI
29	Rosa R, Melisi D, Damiano V, Bianco R, Garofalo S, Gelardi T, Agrawal S, Di Nicolantonio F, Scarpa A, Bardelli A, et al: Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. Clin Cancer Res. 17:6531–6541. 2011. View Article : Google Scholar : PubMed/NCBI
30	Yu D, Putta MR, Bhagat L, Dai M, Wang D, Trombino AF, Sullivan T, Kandimalla ER and Agrawal S: Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction. Antimicrob Agents Chemother. 52:4320–4325. 2008. View Article : Google Scholar : PubMed/NCBI
31	Rodriguez-Torres M, Ghalib RH, Gordon SC and McHutchison JG: IMO-2125, a TLR9 agonist, induces immune responses which correlate with reductions in viral load in null responder HCV patients. Hepatology. 52:336A2010.
32	Kandimalla ER, Bhagat L, Wang D, Yu D, Sullivan T, La Monica N and Agrawal S: Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9. Nucleic Acids Res. 41:3947–3961. 2013. View Article : Google Scholar : PubMed/NCBI
33	Wang M, Bronte V, Chen PW, Gritz L, Panicali D, Rosenberg SA and Restifo NP: Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol. 154:4685–4692. 1995.PubMed/NCBI
34	Huang AY, Gulden PH, Woods AS, Thomas MC, Tong CD, Wang W, Engelhard VH, Pasternack G, Cotter R, Hunt D, et al: The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci USA. 93:9730–9735. 1996. View Article : Google Scholar : PubMed/NCBI
35	Touitou V, Daussy C, Bodaghi B, Camelo S, de Kozak Y, Lehoang P, Naud MC, Varin A, Thillaye-Goldenberg B, Merle-Béral H, et al: Impaired th1/tc1 cytokine production of tumor-infiltrating lymphocytes in a model of primary intraocular B-cell lymphoma. Invest Ophthalmol Vis Sci. 48:3223–3229. 2007. View Article : Google Scholar : PubMed/NCBI
36	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−ΔΔC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
37	Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, Gamelin E, Ponsoda S, Delneste Y, Hebbar M and Jeannin P: Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer. 125:367–373. 2009. View Article : Google Scholar : PubMed/NCBI
38	Greiner JW, Hand PH, Noguchi P, Fisher PB, Pestka S and Schlom J: Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment. Cancer Res. 44:3208–3214. 1984.PubMed/NCBI
39	Boyer CM, Dawson DV, Neal SE, Winchell LF, Leslie DS, Ring D and Bast RC Jr: Differential induction by interferons of major histocompatibility complex-encoded and non-major histo-compatibility complex-encoded antigens in human breast and ovarian carcinoma cell lines. Cancer Res. 49:2928–2934. 1989.PubMed/NCBI
40	Schiavoni G, Mattei F and Gabriele L: Type I interferons as stimulators of DC-mediated cross-priming: Impact on anti-tumor response. Front Immunol. 4:4832013. View Article : Google Scholar
41	Joffre OP, Segura E, Savina A and Amigorena S: Cross-presentation by dendritic cells. Nat Rev Immunol. 12:557–569. 2012. View Article : Google Scholar : PubMed/NCBI
42	Nguyen KB, Salazar-Mather TP, Dalod MY, Van Deusen JB, Wei XQ, Liew FY, Caligiuri MA, Durbin JE and Biron CA: Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J Immunol. 169:4279–4287. 2002. View Article : Google Scholar : PubMed/NCBI
43	Herberman RB, Ortaldo JR, Rubinstein M and Pestka S: Augmentation of natural and antibody-dependent cell-mediated cytotoxicity by pure human leukocyte interferon. J Clin Immunol. 1:149–153. 1981. View Article : Google Scholar : PubMed/NCBI
44	Liu M, Zhou J, Chen Z and Cheng AS: Understanding the epigenetic regulation of tumours and their microenvironments: Opportunities and problems for epigenetic therapy. J Pathol. 241:10–24. 2017. View Article : Google Scholar
45	Dunn J and Rao S: Epigenetics and immunotherapy: The current state of play. Mol Immunol. 87:227–239. 2017. View Article : Google Scholar : PubMed/NCBI
46	Ott PA, Hodi FS and Robert C: CTLA-4 and PD-1/PD-L1 blockade: New immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 19:5300–5309. 2013. View Article : Google Scholar : PubMed/NCBI
47	Mahoney KM, Freeman GJ and McDermott DF: The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther. 37:764–782. 2015. View Article : Google Scholar : PubMed/NCBI
48	Postow MA, Callahan MK and Wolchok JD: Immune checkpoint blockade in cancer therapy. J Clin Oncol. 33:1974–1982. 2015. View Article : Google Scholar : PubMed/NCBI
49	Khalil DN, Smith EL, Brentjens RJ and Wolchok JD: The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 13:273–290. 2016. View Article : Google Scholar : PubMed/NCBI
50	Serra-Bellver P, Valpione S and Lorigan P: Sequential immunotherapy regimens-expect the unexpected. Lancet Oncol. 17:854–855. 2016. View Article : Google Scholar : PubMed/NCBI
51	Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L, et al: Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): An open-label, randomised, phase 2 trial. Lancet Oncol. 17:943–955. 2016. View Article : Google Scholar : PubMed/NCBI
52	Devaud C, John LB, Westwood JA, Darcy PK and Kershaw MH: Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. OncoImmunology. 2:e259612013. View Article : Google Scholar : PubMed/NCBI
53	Arpaia N and Barton GM: Toll-like receptors: Key players in antiviral immunity. Curr Opin Virol. 1:447–454. 2011. View Article : Google Scholar
54	Iwasaki A and Medzhitov R: Toll-like receptor control of the adaptive immune responses. Nat Immunol. 5:987–995. 2004. View Article : Google Scholar : PubMed/NCBI
55	Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264. 2012. View Article : Google Scholar : PubMed/NCBI
56	Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE and Rosenberg SA: Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 114:1537–1544. 2009. View Article : Google Scholar : PubMed/NCBI
57	Mellor AL, Baban B, Chandler PR, Manlapat A, Kahler DJ and Munn DH: Cutting edge: CpG oligonucleotides induce splenic CD19⁺ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol. 175:5601–5605. 2005. View Article : Google Scholar : PubMed/NCBI
58	Fallarino F and Puccetti P: Toll-like receptor 9-mediated induction of the immunosuppressive pathway of tryptophan catabolism. Eur J Immunol. 36:8–11. 2006. View Article : Google Scholar
59	Diab A, Haymaker C, Uemura M, Murthy R, James M, Geib J, Cornfeld M, Swann S, Yee C, Wargo J, et al: A phase 1/2 trial of intratumoral (i.t.) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L)1-refractory melanoma. Ann Oncol. 28(Suppl 5): 1187P2017. View Article : Google Scholar
60	Haymaker C, Uemura M, Murthy R, James M, Wang D, Brevard J, Swann S, Geib J, Cornfeld M, Chunduru S, et al: Translational evidence of reactivated innate and adaptive immunity with intratumoral IMO-2125 in combination with systemic checkpoint inhibitors from a phase I/II study in patients with anti-PD-1 refractory metastatic melanoma. Cancer Res. 77(Suppl 13): 56522017. View Article : Google Scholar